Nadine S Lossi
Overview
Explore the profile of Nadine S Lossi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
406
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kostikas K, Greulich T, Mackay A, Lossi N, Aalamian-Mattheis M, Nunez X, et al.
ERJ Open Res
. 2019 Mar;
5(1).
PMID: 30815470
The association between clinically relevant changes in patient-reported outcomes (PROs) and forced expiratory volume in 1 s (FEV) in patients with chronic obstructive pulmonary disease (COPD) has rarely been investigated....
2.
Buhl R, Criee C, Kardos P, Vogelmeier C, Kostikas K, Lossi N, et al.
Int J Chron Obstruct Pulmon Dis
. 2018 Sep;
13:2557-2568.
PMID: 30197512
Background: No observational studies have evaluated the "real-world" effectiveness of dual bronchodilation comprising a long-acting β-agonist plus a long-acting muscarinic antagonist vs that of triple therapy (long-acting β-agonist plus long-acting...
3.
Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi N, Patalano F, et al.
Int J Chron Obstruct Pulmon Dis
. 2018 May;
13:1229-1237.
PMID: 29713156
Purpose: COPD is a progressive disease characterized by exacerbations and a decline in health status and lung function. Clinically important deterioration (CID) is a composite endpoint used to evaluate treatment...
4.
Worth H, Buhl R, Criee C, Kardos P, Lossi N, Vogelmeier C
Respir Med
. 2017 Sep;
131:77-84.
PMID: 28947047
Introduction: The 2017 update to the Global Initiative for Obstructive Lung Disease (GOLD) strategy document includes recommendations for treatment intensification or step-down in chronic obstructive pulmonary disease (COPD), although recognises...
5.
Kardos P, Vogelmeier C, Worth H, Buhl R, Lossi N, Mailander C, et al.
Respir Med
. 2017 Mar;
124:57-64.
PMID: 28284322
Introduction: DACCORD is an observational, non-interventional study being conducted in German primary and secondary care centres. The study aims to describe the impact of disease (including exacerbations) and treatments over...
6.
Vogelmeier C, Worth H, Buhl R, Criee C, Lossi N, Mailander C, et al.
Int J Chron Obstruct Pulmon Dis
. 2017 Feb;
12:487-494.
PMID: 28203072
Many patients with chronic obstructive pulmonary disease (COPD) receive inhaled corticosteroids (ICSs) without a clear indication, and thus, the impact of ICS withdrawal on disease control is of great interest....
7.
Forster A, Planamente S, Manoli E, Lossi N, Freemont P, Filloux A
J Biol Chem
. 2014 Oct;
289(47):33032-43.
PMID: 25305017
The type VI secretion system (T6SS) is a bacterial nanomachine for the transport of effector molecules into prokaryotic and eukaryotic cells. It involves the assembly of a tubular structure composed...
8.
Hachani A, Lossi N, Filloux A
J Vis Exp
. 2013 Apr;
(73):e50103.
PMID: 23542679
Type VI secretion systems (T6SSs) are molecular nanomachines allowing Gram-negative bacteria to transport and inject proteins into a wide variety of target cells(1,2). The T6SS is composed of 13 core...
9.
Lossi N, Manoli E, Forster A, Dajani R, Pape T, Freemont P, et al.
J Biol Chem
. 2013 Jan;
288(11):7536-7548.
PMID: 23341461
Protein secretion systems in Gram-negative bacteria evolved into a variety of molecular nanomachines. They are related to cell envelope complexes, which are involved in assembly of surface appendages or transport...
10.
Lossi N, Manoli E, Simpson P, Jones C, Hui K, Dajani R, et al.
Mol Microbiol
. 2012 Aug;
86(2):437-56.
PMID: 22906320
In Pseudomonas aeruginosa three type VI secretion systems (T6SSs) coexist, called H1- to H3-T6SSs. Several T6SS components are proposed to be part of a macromolecular complex resembling the bacteriophage tail....